Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NNC9836-0001 in Healthy Participants and Participants With Type 2 Diabetes
NCT07896109Phase 1Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing NNC9836-0001 with Placebo (2 arms). Primary endpoint: Number of Treatment Emergent Adverse Events at week 34. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
NNC9836-0001
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07896109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896109.